Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06867094 · ClinicalTrials.gov registry record · Phase 2
A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis
A Phase 2 study of Colitis, Ulcerative, sponsored by Sanofi.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 204
- Enrollment target
- 20
- Study locations
NCT06867094 is a Phase 2 study of Colitis, Ulcerative that is actively recruiting participants, run by Sanofi. The registered enrollment target is 204 participants, below the 398-participant average among 28 other Colitis, Ulcerative trials with a reported enrollment target (49% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT06867094, a Phase 2 study of Colitis, Ulcerative, is actively recruiting participants, sponsored by Sanofi.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 204 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 2, multinational, multicenter, randomized, double-blind, placebo-controlled, dose ranging study to evaluate the efficacy and safety of SAR441566 in adults with moderate-to-severe UC. The primary objective of this study is to assess efficacy of different doses of SAR441566 on clinical remission in participants with moderate-to-severe ulcerative colitis. This study will include a screening period of up to 28 days (+ 7 calendar days if needed) followed by the main study treatment period of 52 weeks which will be comprised of a double blind (DB) treatment period with 12 weeks of induction period followed by a maintenance period of 40 weeks and 2-week follow-up after end of treatment. Additionally, an Open Label (OL) period of up to 40 weeks will be offered to eligible participants. * The study duration will be up to 59 weeks. * The treatment duration will be up to 52 weeks in the DB arm and up to 40 weeks in the OL arm. * The number of visits will be 12 for the main study treatment period and 8 for the OL treatment period.
Conditions Studied
Interventions
- DRUG SAR441566
- DRUG SAR441566 matching Placebo
Study Locations (20)
Florida
- Novum Research- Site Number : 8400018 - Clermont
- Clinical Research of Osceola- Site Number : 8400012 - Kissimmee
- Wellness Clinical Research - Miami Lakes - 8181 Northwest 154th Street- Site Number : 8400002 - Miami Lakes
- GCP Clinical Research- Site Number : 8400016 - Tampa
Texas
- Gastro Health & Nutrition- Site Number : 8400007 - Katy
- SI Research Associates- Site Number : 8400019 - Lubbock
- Texas Digestive Disease Consultants - Southlake- Site Number : 8400015 - Southlake
Illinois
- GI Alliance - Glenview- Site Number : 8400005 - Glenview
- Illinois Gastroenterology Group- Site Number : 8400004 - Gurnee
New York
- Icahn School of Medicine at Mount Sinai- Site Number : 8400001 - New York
- Queens Village Primary Medical Center- Site Number : 8400011 - Queens Village
Washington
- University of Washington Medical Center- Site Number : 8400014 - Seattle
- Washington Gastroenterology - Tacoma- Site Number : 8400009 - Tacoma
Arizona
- GI Alliance - Arizona Digestive Health - Sun City- Site Number : 8400003 - Sun City
Connecticut
- Bristol Hospital- Site Number : 8400017 - Bristol
Michigan
- University of Michigan Health System - Ann Arbor- Site Number : 8400010 - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 204 participants |
| Start Date | 2025-03-28 |
| Est. Completion | 2028-05-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06867094
The ClinicalTrials.gov registry entry for NCT06867094 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 204 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 398-participant average among 28 other Colitis, Ulcerative trials with a reported enrollment target (49% lower). The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Colitis, Ulcerative appearing as the primary indexed condition, and to 2 interventions - of which SAR441566 is the first listed.
NCT06867094 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Florida, Texas, Illinois.
Frequently Asked Questions
What is clinical trial NCT06867094 about?
NCT06867094 is a clinical study titled "A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis". This is a Phase 2, multinational, multicenter, randomized, double-blind, placebo-controlled, dose ranging study to evaluate the efficacy and safety of SAR441566 in adults with moderate-to-severe UC. The primary objective of this study is to assess efficacy of different doses of SAR441566 on clinical...
What is the current status of trial NCT06867094?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 204 participants. The study started on 2025-03-28. Estimated completion is 2028-05-11.
What conditions does trial NCT06867094 study?
This clinical trial studies the following conditions: Colitis, Ulcerative.
What interventions are being tested in trial NCT06867094?
The interventions under investigation include: SAR441566 (DRUG), SAR441566 matching Placebo (DRUG).
Who is sponsoring clinical trial NCT06867094?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06867094 being conducted?
This trial has 20 study locations across Arizona, Connecticut, Florida, Illinois, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colitis, Ulcerative
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
RECRUITING · Phase 2
-
A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
RECRUITING · Phase 2
-
Pharmacologic Weight Loss as Adjunct Therapy for Ulcerative Colitis in Obese Patients
RECRUITING · Phase 2
-
A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease
ACTIVE NOT RECRUITING · Phase 2
-
VTX002 Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.